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Abstract
Granulosa cell tumors (GCTs) carry a risk of recurrence also at an early stage,
but reliable prognostic factors are lacking. We assessed clinicopathological
prognostic factors and the prognostic roles of the human epidermal growth
factor receptors (HER 2–4) and the transcription factor GATA4 in GCTs. We
conducted a long-term follow-up study of 80 GCT patients with a mean fol-
low-up time of 16.8 years. A tumor-tissue microarray was immunohistochemi-
cally stained for HER2–4 and GATA4. Expression of HER2–4 mRNA was
studied by means of real time polymerase chain reaction and HER2 gene
amplification was analyzed by means of silver in situ hybridization. The results
were correlated to clinical data on recurrences and survival. We found that
GCTs have an indolent prognosis, with 5-year disease-specific survival (DSS)
being 97.5%. Tumor recurrence was detected in 24% of the patients at a med-
ian of 7.0 years (range 2.6–18 years) after diagnosis. Tumor stage was not
prognostic of disease-free survival (DFS). Of the molecular prognostic factors,
high-level expression of HER2, and GATA4, and high nuclear atypia were
prognostic of shorter DFS. In multivariate analyses, high-level coexpression of
HER2 and GATA4 independently predicted DFS (hazard ratio [HR] 8.75, 95%
CI 2.20–39.48, P = 0.002). High-level expression of GATA4 also predicted
shorter DSS (HR 3.96, 95% CI 1.45–12.57, P = 0.006). In multivariate analyses,
however, tumor stage (II–III) and nuclear atypia were independent prognostic
factors of DSS. In conclusion HER2 and GATA4 are new molecular prognostic
markers of GCT recurrence, which could be utilized to optimize the manage-
ment and follow-up of patients with early-stage GCTs.
Introduction
Granulosa cell tumor (GCT) is a rare subtype of ovar-
ian cancer, representing 3–5% of all ovarian malignan-
cies. GCT presents with the juvenile and the more
common adult subtype with mean age at diagnosis
between 50 and 54 years [1]. Adult GCTs are character-
ized by an indolent, albeit unpredictable, course of dis-
ease with a recurrence risk of 20–30% even with early-
stage disease [2, 3]. Recently, adult GCTs were shown
to have a distinct molecular background since a single
somatic mutation (402C->G) in the gene encoding for
Forkhead Box L2 (FOXL2) was found in 90–97% of
GCTs [4–7]. The functional role of the FOXL2 muta-
tion in GCTs remains unresolved. Tumor stage (FIGO
stages II–IV) is the only definitive prognostic factor
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affecting GCT recurrence and survival [2, 8–10]. How-
ever, in view of the fact that the majority of GCTs (80–
90%) are diagnosed at stage I [3, 8], new prognostic
factors are needed.
Human epidermal growth factor receptors (HERs) are
a group of transmembrane tyrosine kinase receptors
including HER1, HER2, HER3, and HER4, which play
essential roles in ovarian granulosa cell proliferation and
survival [11, 12]. Overexpression of HER2 (ErbB2/neu) is
prognostic of more aggressive disease in several cancers,
including breast, gastric, and epithelial ovarian carcino-
mas [13–15]. Moreover, HER2 can be therapeutically tar-
geted with a monoclonal antibody trastuzumab and a
small molecule HER2/EGFR (epidermal growth factor
receptor) inhibitor lapatinib in the treatment of HER2
overexpressing breast and gastric cancers [16]. Previously,
few studies have assessed the expression of HER2, HER3,
and HER4 in GCTs, and found GCTs positive for HER3
and HER4 [17–20]. The expression of HER2 in GCTs
remains controversial; three studies revealed positive
expression of HER2 in GCTs [17, 18, 20], while five oth-
ers did not [19, 21–24]. The prognostic significances of
HER2, HER3, and HER4 expressions and HER2 gene
amplification in GCTs are unknown.
GATA4 is a zinc-finger transcription factor that plays a
crucial role in ovarian and granulosa cell development
and function [25, 26]. The majority of GCTs express
GATA4, and high-level expression is associated with
higher tumor stage and increased recurrence risk [27].
Further, GATA4 has been suggested to have a role in
GCT pathogenesis by inhibiting apoptosis through acti-
vating anti-apoptotic B-cell lymphoma-2 [28, 29].
The relative rarity and long natural history of GCTs
has hindered the identification of solid prognostic factors
to guide therapeutic decisions in early-stage disease. We
have previously screened a tumor tissue microarray
(TTMA) for multiple factors of possible prognostic signif-
icance [27–32]. In search of new prognostic tools, we
herein performed a long-term follow-up study to evaluate
potential prognostic factors of GCTs. In addition to eval-
uating GATA4 as a potential prognostic factor, we charac-
terized the expression levels of HER2-4, as well as gene
copy numbers of HER2 in GCTs and correlated the
expression levels to tumor recurrence and survival in a
cohort of 80 GCT patients.
Material and Methods
Patients and tumor samples
The Ethics Committees of Helsinki University Central
Hospital (HUCH) and the National Supervisory Author-
ity of Welfare and Health in Finland approved this study.
The clinical data and tumor samples were collected from
80 primary GCT patients diagnosed at HUCH between
1971 and 2003; the median year of diagnosis was 1990. In
the follow-up study, we invited all living patients no
longer in controls to a clinical visit, and 31 of them were
examined by way of gynecologic examination, Pap smear,
pelvic ultrasonography and assay of serum markers.
Informed consent was obtained from these patients in the
follow-up study. Follow-up data on 20 living and 29
deceased patients were taken from hospital files and reli-
able follow-up data was available from all 80 patients.
Follow-up was performed until death (n = 29) or May
2012; the mean follow-up time was 16.8 years (SD
9.1 years). The causes of death were collected from death
certificates retrieved from the Finnish causes of death
registry.
Tumor tissue samples from 26 primary and five recur-
rent GCT patients were collected for Real time polymer-
ase chain reaction (PCR) analyses during 1990–2009.
RNA was isolated from frozen tumor tissue as described
previously [31]. The RNA quality was assessed according
to the instructions provided with an Agilent 2100 bioana-
lyzer Eukaryote Total RNA Nano kit (Agilent technolo-
gies, Santa Clara, CA).
Immunohistochemistry and silver in situ
hybridization
A previously constructed TTMA of 80 primary and 13
recurrent GCTs was utilized [27]; all diagnoses were
reevaluated as adult GCTs by an expert pathologist (R.
B.). The 13 recurrent GCTs in the TTMA were analyzed
only for expression of the factors and excluded from the
recurrence and survival analyses. Tumor subtype and the
degree of nuclear atypia were evaluated, and mitotic index
was graded as “high” when there were ≥5 mitotic figures
per 10 high-power fields (HPFs) and “low” when there
were <5 mitotic figures per 10 HPFs [27]. Paraffin-
embedded sections of the TTMA were stained for expres-
sion of HER2 (sc-33684; Santa Cruz Biotechnology Inc.,
Dallas, TX) and phosphorylated (P-) HER2 (ab47755; Ab-
cam, Cambridge, UK), HER3 (sc-415; Santa Cruz Bio-
technology Inc.) and P-HER3 (#4791; Cell Signaling
Technology Inc., Danvers, MA) and HER4 (sc-283; Santa
Cruz Biotechnology Inc.) and P-HER4 (sc-33040, Santa
Cruz Biotechnology Inc.) as described previously [27].
Each sample was analyzed for the intensity of staining (all
antigens) and the percentage of positive cells (GATA4),
decided as a consensus of opinion of two researchers (N.
A., M. A.). The tumors were grouped into high-level
(>80% of positive cells showing high-level or intermediate
staining intensity) or low-level expression groups, the lat-
ter also containing the nonstaining tumors. Silver in situ
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hybridization (SISH) of the TTMA for HER2 gene copy
number was conducted as described [33], with minor
modification; hybridization was performed at 52°C for
10 h. The HER2 copy numbers were evaluated as a con-
sensus of opinion of three researchers (A. F., N. A., R.
B.). Low-level amplification was defined as three to six
HER2 signals per nucleus.
Real time PCR
RNA was reverse transcribed using a TaqMan reverse
Transcription kit (Applied Biosystems, Branchburg, NJ)
in 40-lL reaction volume. The following primers were
used for real time PCR: HER2, forward 50-GCTGGCTCT
CACACTGATA, reverse 50-AGACAGTGCGCGTCAG;
HER3 forward 50-GCTCCCTTCACCCTCT, reverse 50-T
CCCAGGACACACTGC; and HER4 forward 50-GGAAG
GATCTGCATAGAGTCT, reverse 50-TCCATGGCATGT
GAGGA. The b-actin gene was used as a reference gene
and the primers used were forward 50-CTGACGGC
CAGGTCATCAC and reverse 50-CAGACAGCACTGT
GTTGGC. SYBR Green PCR Master mix (Applied Biosys-
tems) was utilized in a 20-lL reaction volume. The
annealing temperature was 60°C, with 40 cycles, plus the
dissociation step. A standard curve method was applied
and analyses were performed in triplicate using an ABI
PRISM 7700 sequence detection system (Applied Biosys-
tems) according to the manual.
Data analysis
Disease-free survival (DFS) was determined as the time
from primary tumor operation to the first recurrence.
Disease-specific survival (DSS) was determined as the
time from diagnosis to death from GCT; other causes of
death were censored. Associations between the immuno-
histochemical data and clinical characteristics were ana-
lyzed by using contingency tabling and v2 or Fisher’s
exact tests, as appropriate. Distribution of continuous
variables were evaluated with Shapiro–Wilk’s test and
normally distributed variables were correlated with one-
way analysis of variance (ANOVA) and Student’s t-test
(age at diagnosis), and non-normally distributed with
Mann–Whitney test (follow-up time, RNA expression
data). Univariate Cox regression analysis and Kaplan–
Meier log-rank test were performed for DFS and DSS
according to the methodology. The Kaplan–Meier plots
are displayed leaving a minimum of five subjects at risk,
except in Figure 2A. Multivariate analyses were conducted
using nominal logistic regression for associations with
recurrence and the Cox regression model was used for
DFS and DSS. Significant factors in univariate analyses
were included into the multivariate models. The analyses
were performed with JMP 9.0.0 (SAS Institute Inc., Cary,
NC) software. A P-value <0.05 (two-sided test) was con-
sidered significant.
Results
Adult GCT recurs even in the early stages
Patient characteristics and recurrences in 80 cases of pri-
mary GCTs are summarized in Table 1. Eighteen (24%)
patients had a recurrence during the follow-up period; 15
(83%) of these were of stage I. The median time to recur-
rence was 7.0 years (range 2.6–18 years, mean 7.7, SD 4.5).
Six (33%) of the recurrences occurred within 5 years, 14
(78%) within 10 years, and 17 (94%) within 15 years after
the diagnosis. One patient had a recurrence after 18.4 years
after the primary diagnosis. Tumor recurrence was associ-
ated only with a high degree of nuclear atypia; recurrence
was not associated with any other factors in Table 1 (Fish-
er’s exact test, data not shown). Follow-up times among
the patients with recurrence were similar to those among
those with no recurrence (P = 0.7).
Survival data were available for all 80 patients. By the
end of the follow-up period, 51 (63.8%) patients were
alive, 11 (13.7%) had died of GCT, and 18 (22.5%) had
died of other causes. The 5-, 10-, and 15-year DSS rates
were 97.5%, 91.9%, and 89.9%, respectively. In stage I
patients, 10-year DSS was significantly greater (95.8%,
P = 0.02), than in stage II (83.3%) or stage III (33.3%)
patients. The median time between diagnosis and death
from GCT was 9.7 years (range 0.1–33.9 years). One
patient with inoperable stage IIIc GCT died of the disease
3 weeks after primary tumor operation. If the tumor
recurred, the 10-year DSS was 72.2%. The median time
between the first recurrence and death was 6.4 years
(range 0.3–20.4 years). Of the clinicopathological factors,
only nuclear atypia was associated with DSS (P = 0.01);
no other factors in Table 1 correlated to DSS (Fisher’s
exact test, data not shown).
HER2, HER3, and HER4 are expressed in GCTs
In a search for new prognostic tools, the TTMA was
immunohistochemically stained for native and phosphory-
lated (P-) HER2-4; data for the native proteins are summa-
rized in Table 2. We found positive staining for HER2 in 84
(98%) tumors and in 79 (90%) of the tumors, HER2 was
also expressed in its phosphorylated form. P-HER3 was
expressed in 8 (9%) of the tumors and P-HER4 in 74 (84%),
respectively. We also analyzed gene copy number alterations
of HER2 by means of SISH in 91 GCTs and found low-level
gene amplification (three to six signals) ofHER2 in eight pri-
mary GCTs. Low-level gene amplification was not associated
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with tumor size, stage, nuclear atypia, or recurrence. Data
on GATA4 staining in 80 primary and 13 recurrent tumors
have been presented previously [27]. Based on the immuno-
staining, the tumors were divided into groups of high and
low expression; representative images of the groups are pre-
sented in Figure 1. The expression levels of HER2–4 did not
correlate to each other and there were no differences
between the expression patterns of primary and recurrent
GCTs. We found a strong positive correlation between
HER2 and GATA4 protein levels in primary GCTs
(P = 0.002), and also in all the tumors (P = 0.0006) (data
not shown). In primary GCTs, high-level expression of both
HER2 and high GATA4 correlated positively to higher
tumor stage (stages II–III and Ib–III, P < 0.05). Further-
more, we found that high-level expression of HER2
(P = 0.02) and GATA4 (P = 0.006) were associated with
tumor recurrence.
In order to verify the mRNA expression levels of
HER2–4 in GCTs, we performed real time PCR of HER2–
4 in 31 GCTs. We found that both primary and recurrent
tumors similarly expressed mRNA for HER2–4. The
expression of HER2 was robust (median 1.1 ng, range
0.5–2.5 ng), whereas the levels of HER3–4 were low
(HER3; median 0.3 ng, range 0.06–7.0, HER4; median
0.3 ng, range 0.03–7.0 ng). The RNA expression levels did
not correlate to clinical parameters (e.g., primary tumor
size, stage) or probability of recurrence (data not shown).
HER2, GATA4, and nuclear atypia are
prognostic of GCT recurrence
The effects of stage, HER2, GATA4, and nuclear atypia
on GCT prognosis were investigated by means of Kaplan–
Meier analyses of DFS (Fig. 2). In our analyses, tumor
Table 1. Clinical and tumor characteristics of 80 primary GCT patients.
Total (n = 80)
No recurrence (n = 62) Recurrence (n = 18)
n (% of total) n (% of characteristic)
(A) Patient characteristics
Mp status
PreMp 37 (46.2) 25 (67.6) 12 (32.4)
PostMp 43 (53.8) 37 (86.0) 6 (14.0)
Stage
I 71 (88.8) 56 (78.9) 15 (21.1)
Ia 50 (70.4) 40 (80.0) 10 (20.0)
Ib 1 (1.4) 1 (100) 0 (0)
Ic 20 (28.2) 15 (75.0) 5 (25.0)
IO rupture* 12 (60.0) 8 (66.7) 4 (33.3)
II 6 (7.5) 4 (66.7) 2 (33.3)
III 3 (3.8) 2 (66.7) 1 (33.3)
Treatment
Surgery only 65 (81.3) 50 (76.9) 15 (23.1)
Surgery + C 12 (15.0) 10 (83.3) 2 (16.7)
Surgery + R 1 (1.3) 0 (0) 1 (100)
Surgery + C + R 2 (2.5) 2 (100) 0 (0)
Age at diagnosis (years), median (range) 52 (19–87) 52 (19–87) 50 (28–76)
Follow-up time (years), median (range) 13.9 (0.1–36.7) 13.6 (0.1–36.7) 15.6 (4.5–34.0)
(B) Tumor characteristics
Tumor size
≥10 cm 32 (40.0) 23 (71.9) 9 (28.1)
<10 cm 48 (60.0) 39 (81.3) 9 (18.7)
Subtype
Sarcomatoid 24 (30.0) 16 (66.7) 8 (33.3)
Differentiated 56 (70.0) 46 (82.1) 10 (17.9)
Nuclear atypia
High 18 (22.5) 11 (61.1) 7 (38.9)
Low 62 (77.5) 51 (82.3) 11 (17.7)
Mitotic index
High 20 (25.0) 13 (65.0) 7 (35.0)
Low 60 (75.0) 49 (81.7) 11 (18.3)
Mp, menopause; IO, intraoperative; C, chemotherapy; R, radiation therapy.
*IO tumor rupture as percentage of stage Ic tumors.
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stage was not prognostic as regards DFS (Fig. 2A and B).
Within the first 5 years, however, there was an increased
risk of recurrence among stage Ic patients compared with
stage Ia–b patients (hazard ratio [HR] 10.64, 95% confi-
dence interval [95% CI] 1.57–208.12, P = 0.01) (Fig. 1B).
However, the difference was not significant after 10 or
15 years of follow-up.
High-level expression of HER2 (Fig. 2C, Table 3A) and
GATA4 (Fig. 2D, Table 3A) were prognostic of shorter
DFS, and DFS was even shorter if the primary tumor co-
expressed high levels of both HER2 and GATA4 (Fig. 2E,
Table 3A). Within 10 years, 48.1% (SE 14.3%) of the
tumors coexpressing high-level GATA4 and HER2 had
recurred, while only 8.7% (SE 4.7%) of the low-GATA4-
and low-HER2-expressing tumors had recurred. Both
high-level GATA4 and high-level HER2 predicted DFS
independently of tumor stage (Table 3A). High-level
nuclear atypia was also prognostic of shorter DFS
(Fig. 2F), as it also was after adjusting for tumor stage
(Table 3A).
In order to find independent prognostic factors as
regards DFS, we carried out multivariate analysis using
the significant prognostic factors shown in Table 3A. We
found that nuclear atypia was an independent predictor
of DFS, again also after adjusting for tumor stage
(Table 3B). However, high-level coexpression of HER2
and GATA4 was an even stronger independent prognostic
factor when analyzed with nuclear atypia (Table 3B), and
also when analyzed only in stage I (HR 5.62, 95% CI
1.45–23.48, P = 0.01) and in stage Ia (HR 11.5, 95% CI
1.76–79.41, P = 0.01) tumors. However, in a multivariate
comparison of the molecular prognostic factors, GATA4
was superior to HER2 in predicting DFS (Table 3C). The
results were not affected by adjusting for different groups
of tumor stage (Ia vs. Ib–III or I vs. II–III).
Table 2. Protein expression levels of 80 primary and 13 recurrent
GCTs.
Immunohistochemistry and SISH n (%)
Factor Expression level
Primary
(n = 80)
Recurrent
(n = 13)
HER2 High 17 (22.7) 4 (33.3)
Low 58 (77.3) 8 (66.7)
HER3 High 18 (23.1) 8 (66.7)
Low 60 (76.9) 4 (33.3)
HER4 High 54 (73.0) 10 (83.3)
Low 20 (27.0) 2 (16.7)
HER2 SISH 3–6 copies 8 (10.1) 0 (0)
No amplification 71 (89.9) 12 (100)
GATA4 High 34 (42.5) 5 (38.5)
Low 46 (57.5) 8 (61.5)
HER2 + GATA4 High H + high H 13 (18.0) 3 (25.0)
High H + low G 1 (1.4) 1 (8.3)
Low H + high G 20 (27.8) 2 (16.8)
Low H + low G 38 (52.8) 6 (50.0)
SISH, silver in situ hybridization; H, HER2; G, GATA4.
A B
C D
E F
G H
I J
Figure 1. Representative images of HER2, HER3, HER4, and GATA4
immunohistochemical staining and HER2 silver in situ hybridization in
adult GCTs. A GCT sample with (A) high-level expression and (B) low-
level expression of HER2 on the cell membrane. High-level expression
of HER3 localized into the nucleus and cytoplasm (C). In the majority
of GCTs HER3 immunostaining was negligible (D). HER4 was localized
into the cell membrane in both (E) high-level and (F) low-level
expressing GCTs. Eight GCTs showed small-scale amplification of the
HER2 gene (G), while gene copy number was normal in most tumors
(H). High-level nuclear expression of the transcription factor GATA4 (I)
and a GCT with low-level GATA4 expression (J). The magnification of
(A–F, I, and J) is 209 and the scale bar represents 50 lm. The
magnification of (G and H) is 1009 and the scale bar represents
10 lm.
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Tumor stage, GATA4, and nuclear atypia are
prognostic of DSS
In Kaplan–Meier analyses, patients with stage II–III
tumors had shorter DSS (Fig. 3A, Table 3D) when com-
pared with stage I patients. However, it must be noted
that the number of stage II–III patients was relatively
small (n = 9). DSS was similar in stage Ia patients when
compared with those with stage Ib–III disease (Fig. 3B).
Expression of HER2 was not associated with DSS
(Fig. 3C). High-level GATA4 expression (Fig. 3D,
Table 3D) and high-level nuclear atypia were prognostic
as regards DSS (Fig. 3E, Table 3D). In multivariate analy-
ses, stage II–III and high-level nuclear atypia both inde-
pendently predicted poorer DSS (Table 3D).
Discussion
An adult GCT is characterized by slow and indolent
growth, but carries a risk of recurrence even relatively late
A B
C D
E F
Figure 2. Kaplan–Meier plots of disease-free survival (DFS) to the first recurrence in 80 GCT patients according to tumor stage, expression of
HER2 and GATA4, and nuclear atypia. Recurrence-free proportion of patients with either stage I, II, or III GCTs (A), and in patients with stage I
tumors (B). The recurrence-free proportion of patients with tumors expressing low or high levels of HER2 (C), GATA4 (D), and in combinations (E)
and in tumors having low-level or high-level nuclear atypia (F). H, HER2; G, GATA4. The Kaplan–Meier plot for the low G + high H group is not
shown in E due to small sample size (n = 1), and the P-value in E is derived from analysis between the low H + low G versus the high H + high G
expression groups. Log-rank test, differences between groups were considered significant when P < 0.05 (*P < 0.05, **P < 0.01).
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after primary treatment. Tumor stage is the only prognos-
tic factor in GCTs, however, in view of the fact that the
majority of GCT patients are diagnosed with early-stage
disease, a major challenge has been the identification of
molecular prognostic markers to predict tumor recurrence.
Overexpression of HER2 is an adverse prognostic factor in
breast [14], gastric [34], pancreatic [35], lung [36], and
ovarian carcinomas [13] and we previously reported that
high-level expression of the transcription factor GATA4 is
associated with more aggressive GCTs [27]. Therefore, we
now evaluated the prognostic significance of these factors
in our large series of GCT patients with prolonged follow
up. In addition, we assessed clinical prognostic factors as
regards GCT recurrence and survival.
Because of the rarity and the long disease course of
GCTs, prognostic factors have been difficult to establish
[3, 37]. There are several advantages of this study when
compared with previous studies on prognostic factors in
GCTs. First, only histologically reconfirmed adult GCTs
were included in the study; without reevaluation the
rate of false original diagnoses of GCTs can be up to
50% [38]. Second, an extended follow-up period is
needed in order to detect all recurrent GCTs [10]; we
clinically examined over 30 patients in the follow-up
study, and we were thus able to achieve a follow-up
period of over 10 years in the majority (84%, n = 67)
of the patients alive. This allowed us to reliably evaluate
prognostic factors in most cases of possible recurrence.
One disadvantage of this study is the small number of
patients diagnosed with advanced tumors; there were no
patients with stage IV GCTs, and only three patients
with stage III tumors. However, this is a typical
characteristic of GCT, and the numbers of early-stage
tumors correspond to those reported in previous GCT
studies [3, 9].
In accordance with the results of previous studies [17–
20], we found positive expression of HER2-4 in GCTs.
HER2 was positive in the majority of GCTs, and also in
its phosphorylated form. These findings contradict the
results of some of the earlier studies where GCTs were to
be negative of HER2 [19, 21–24]. These mostly immuno-
histochemical studies involved the use of various methods
and antibodies [19, 21]. In concordance with previous
results [23], we found that HER2 amplification is rare in
Table 3. Univariate and multivariate Cox regression analyses regarding disease-free survival (DFS) and disease-specific survival (DSS) in 80 GCT
patients.
(A) Univariate and stage-adjusted risk factors for DFS
Factor Level HR (95% CI) P-value AHR (95% CI) P-value
HER2 High 3.15 (1.20–8.00) 0.01* 3.02 (1.11–7.94) 0.03*
GATA4 High 4.04 (1.52–12.64) 0.004** 3.96 (1.45–12.57) 0.006**
HER2 and GATA4 High + high 6.61 (1.98–25.44) 0.002** 6.40 (1.78–25.6) 0.005**
Nuclear atypia High 3.00 (1.10–7.66) 0.02* 3.21 (1.17–8.03) 0.03*
(B) Multivariate; Independent risk factors for DFS
Factor Level HR (95% CI) P-value AHR (95% CI) P-value
HER2 High 2.19 (0.79–6.00) 0.1 2.32 (0.82–6.38) 0.1
GATA4 High 2.70 (0.91–8.98) 0.07 2.83 (0.94–9.46) 0.06
Nuclear atypia High 2.81 (1.01–7.38) 0.04* 2.91 (1.04–7.72) 0.04*
HER2 and GATA4 High + high 6.30 (1.85–24.59) 0.003** 8.75 (2.20–39.48) 0.002**
(C) Multivariate; Comparison of the molecular prognostic factors for DFS
Factor Level HR (95% CI) P-value AHR (95% CI) P-value
HER2 High 2.16 (0.79–5.82) 0.1 2.25 (0.77–6.32) 0.1
GATA4 High 3.02 (1.07–9.87) 0.04* 3.09 (1.06–10.14) 0.04*
(D) Univariate and multivariate risk factors for DSS
Univariate Multivariate
Factor Level HR (95% CI) P-value HR (95% CI) P-value
Stage II–III 6.27 (1.26–26.34) 0.03* 5.93 (1.12–27.86) 0.04*
GATA4 High 3.97 (1.14–18.21) 0.03* 2.82 (0.74–13.54) 0.1
Nuclear atypia High 6.02 (1.72–23.59) 0.006** 6.56 (1.83–26.34) 0.004**
HR, hazard ratio; AHR, stage-adjusted hazard ratio; CI, confidence interval. *P < 0.05, **P < 0.01.
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GCTs. HER2 is a therapeutic target in breast and gastric
cancers [16], and clinical studies concerned with targeting
EGF receptors in epithelial ovarian cancer are ongoing
(www.clinicaltrials.gov). GCTs respond to the targeting of
EGF receptors HER3-4 with a cytotoxic ligand in vitro
[17], and the results of this study imply that HER2 is also
a potential target in the development of new treatment
strategies for GCT patients, especially for patients with
high-risk HER2-expressing tumors.
GATA4 is a crucial regulator of granulosa cell func-
tion [26, 39] and putatively plays an important role in
GCT pathogenesis by regulating GCT cell survival and
apoptosis [28, 29]. The functional role of the patho-
gnomonic FOXL2 mutation in GCTs is unknown, but
it has been suggested to act as a tumor suppressor in
granulosa cells by mediating apoptosis [40, 41]. Fur-
thermore, recent molecular analyses suggest that the
pathognomonic FOXL2 mutation causes imbalances in
transforming growth factor (TGF)-b signaling, and
more precisely, impaired interaction with SMAD tran-
scription factors [42, 43]. GATA4 has been shown to
interact with SMAD3 [25], a member of the TGF-b
signaling cascade, and recently also with FOXL2 [44],
thus linking GATA4 to the fundamental genetic changes
in GCT pathogenesis. Moreover, GATA4 protein expres-
sion has been found to correlate positively with that of
A B
C D
E
Figure 3. Kaplan–Meier plots of disease-specific survival (DSS) of GCT patients according to tumor stage, expression of HER2 and GATA4, and
nuclear atypia. Proportion of patients surviving with either stage I or II–III tumors (A), and with tumors of stage Ia or Ib–II (B). Proportion of
patients surviving with tumors expressing low or high levels of GATA4 (C) and HER2 (D) and with tumors having low- or high-level nuclear atypia
(E). Log-rank test, differences between groups were considered significant when P < 0.05 (*P < 0.05, **P < 0.01).
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HER2 in breast cancer [45] and functional studies have
shown that GATA4 directly binds HER2 promoter and
regulates its expression [46]. In GCTs, we found that
expression of GATA4 and HER2 strongly colocalized
and together delineated an even more aggressive disease.
Indeed, GATA4 may be one of the transcription factors
mediating HER2 overexpression in GCTs. In addition,
epigenetic changes may attribute to the biological roles
of HER2 and GATA4 in GCTs. Increased promoter
methylation of GATA4 has been shown in epithelial
ovarian cancers [47]. Furthermore, promoter methyla-
tion of HER2 may mediate chemo resistance in breast
and lung cancers [48, 49]. Epigenetic modification of
HER2–4 and GATA4 are unknown in GCTs. Promoter
methylation of some genes (e.g., ER-a, BRCA1) has
been shown to exist in GCTs [50], but their roles
remain unknown. In this study, GATA4 was an inde-
pendent prognostic factor in predicting GCT recurrence
and also delineated survival of GCT patients. High-level
expression of GATA4 in the primary tumor led to an
average threefold increased recurrence risk, indepen-
dently of tumor stage. In multivariate analyses, GATA4
was superior to HER2 in predicting DFS. These data
suggest that GATA4 could be used as a single prognos-
tic marker, including in early-stage GCTs.
On the basis of the present data, nuclear atypia seems to
be the most potent factor in predicting DSS of GCT
patients. However, one must keep in mind the fact that the
number of GCT-related deaths was relatively small in this
study. Furthermore, based on previous studies on GCTs,
the prognostic role of nuclear atypia is controversial; in
four studies it has been found to be associated with worse
prognosis [51–54], whereas in two studies this has not been
confirmed [55, 56]. Furthermore, nuclear atypia is an
unspecific morphological characteristic associated with
great inter- and intraobserver variation, underscoring the
need for specific molecular markers for GCTs. In conclu-
sion, we have shown that HER2 and GATA4 are new prog-
nostic factors for GCT. It is to be hoped that the
identification of solid prognostic markers, coupled with
increasing understanding of GCT pathogenesis, will lead
toward more targeted treatment and follow-up strategies
for GCT patients.
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